Clinical approaches to non-alcoholic fatty liver disease
about
Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancerRole of diet on non-alcoholic fatty liver disease: An updated narrative reviewObesity as an emerging risk factor for iron deficiencyAn evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharidesUrinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver diseaseSilencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease.Molecular pathways in non-alcoholic fatty liver disease.The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study.Surgical treatment of nonalcoholic fatty liver disease in severely obese patientsTreatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work reviewAssociation between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease.Non-alcoholic fatty liver disease: The diagnosis and management.Opposite cross-talk by oleate and palmitate on insulin signaling in hepatocytes through macrophage activationCirculating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic SteatohepatitisIntegrated Haematological Profiles of Redox Status, Lipid, and Inflammatory Protein Biomarkers in Benign Obesity and Unhealthy Obesity with Metabolic Syndrome.Disparate metabolic effects of blackcurrant seed oil in rats fed a basal and obesogenic diet.Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report.Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease.Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort studyDeciphering non-alcoholic fatty liver disease through metabolomics.Creatine supplementation as a possible new therapeutic approach for fatty liver disease: early findings.Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases.Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis.Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery.Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway.Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.Identification of Plants That Inhibit Lipid Droplet Formation in Liver Cells: Rubus suavissimus Leaf Extract Protects Mice from High-Fat Diet-Induced Fatty Liver by Directly Affecting Liver Cells.Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis.Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation.Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease.Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated DisordersThe Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 InhibitionConcepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease
P2860
Q26741524-AAFE54AE-66AC-4FDD-9DD4-F5F4FFD96BC9Q27000333-C9A56A0C-6C2E-44AE-BB57-41FA4D01DC37Q27000369-40CB89DE-993F-4DFE-A3A9-64AF2F554C0DQ28385065-2602C78D-0716-42B2-9707-D224FA5E8257Q33599564-9C5FD6D4-F8EE-4CA5-8187-CE7FAA684285Q33862990-0FCB217B-37D5-45E5-BD31-4D2A2B16D2D4Q33890230-AA683A2C-30B4-4D5F-9436-A5CD144D1F4FQ34303169-B82B0A88-F505-4032-AC11-6F2FAE2DFE33Q34446294-C9437E29-4592-44EB-B6B3-F5AFDF4AC016Q35037545-6950877C-0194-48A9-BED8-E0769256D933Q35131597-707261A1-DFD7-48D7-B755-86CB1DA92F27Q35543956-A6E0ABEA-25ED-43E9-83C7-807C24ACF687Q35561091-3CD0B70E-F498-420A-AAE9-0ADD07353A84Q35576521-7D12FCBB-0480-4E44-8CA2-7CD56A63D438Q35666218-9612B614-13C5-46D5-9A81-2527ACBAD6D0Q35673707-AC982EB9-74E6-4B13-8400-7633FC3392B8Q35967988-90DB846F-8606-453A-A383-80E728ED99F9Q36264022-1EBE74DE-B634-4664-8F93-F3A4BD1C104AQ36315771-38984043-770C-4935-8B16-0F6AD5F8ABD3Q36572295-818FBBD6-A4AE-476F-8982-B0F42CCC6C13Q38252319-C4C5908A-B362-429A-B7AE-CC9F5C0C4163Q38718576-B4D5F6C0-BA97-412D-9EFD-E5D178D4A5B3Q38819558-63B7C5E1-86B8-43F0-9520-080B137040D3Q40314706-6E88751A-6FF6-410B-91E8-37DC63F37C72Q41003932-1AC93161-CF0E-44A8-A8A7-EA999515B61EQ41878667-CC116ECF-EE07-4F8F-87AA-2E87911EBCABQ42000430-DC1CA7BA-888F-4A22-90FE-C463E8E29DF0Q42146258-6231BB3F-6FC2-4853-B921-B921A48D5A4FQ46554515-E26948EB-9898-48AB-8360-94AEA7982340Q51176303-6551123D-0C07-4031-9A6F-B209F9A79C3BQ51268571-FEA447C8-9982-4664-A95E-FD96554B4A37Q52902850-E3F9429E-B4E3-474E-B133-8B3C241872B8Q54766462-87F4F158-366D-4A29-A35A-F7C312B5AEA9Q57191819-B5F4D13D-5FA9-42F8-B81A-0EC49835A5E7Q57300008-32B17B9F-62B9-43F6-A8C5-C044F859ADB7Q59050456-24573090-CC6D-4EBB-9074-4C84F367D21C
P2860
Clinical approaches to non-alcoholic fatty liver disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical approaches to non-alcoholic fatty liver disease
@en
Clinical approaches to non-alcoholic fatty liver disease.
@nl
type
label
Clinical approaches to non-alcoholic fatty liver disease
@en
Clinical approaches to non-alcoholic fatty liver disease.
@nl
prefLabel
Clinical approaches to non-alcoholic fatty liver disease
@en
Clinical approaches to non-alcoholic fatty liver disease.
@nl
P2860
P356
P1476
Clinical approaches to non-alcoholic fatty liver disease
@en
P2093
Johane P Allard
Katherine J P Schwenger
P2860
P304
P356
10.3748/WJG.V20.I7.1712
P407
P577
2014-02-01T00:00:00Z